Peptide deformylase inhibitors

1. A compound according to Formula (1):

wherein:

Y represents —C(O)— or a covalent bond;

R represents arylene, heteroarylene or a covalent bond;

Z represents —CH 2 —, —NR3—, —O—, —C(O)NR3—, —NR3C(O)— or —CH═CH— when R is a substituted arylene or a substituted heteroarylene, and represents —CH 2 — or —CH═CH— when R is a covalent bond; R3 is hydrogen, C 1-3 substituted alkyl, and (CH 2 ) 0-2 —C 3-6 substituted carbocycle;

R1 is selected from the group consisting of:

hydrogen, C 1-3 substituted alkyl, C 2-3 substituted alkenyl, C 2-3 substituted alkynyl, and

(CH 2 ) 0-2 —C 3-6 substituted carbocycle;

m is equal to 0 when Z =—NR3— or —CH 2 —; or m is equal to 0 or 1 when Z =—O—, —C(O)NR3— or —NR3C(O)—; or m is is an integer between 0 and 6 when Z =—CH═CH—;

n is an integer equal to or greater than 2, appropriately chosen so that the number of atoms in the macrocyclic ring ranges from 13 to 16;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein R1 represents hydrogen; or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 , with the following absolute configuration:

or a pharmaceutically acceptable salt, thereof.

4. The compound according to claim 3 selected from the group consisting of:

N-{[(5R)-16-(Dimethylamino)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-(4-Morpholinyl)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-(Cyclopropylamino)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-(4-Morpholinyl)-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-Methyl-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-4-Oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-Methyl-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-(4-Morpholinyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-(2-Furanyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-(4-Morpholinyl)-4-oxo-2,3,14,16,17-pentaazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-(Dimethylamino)-4-oxo-2,3,14,16,17-pentaazabicyclo [11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-4-Oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-14-Methyl-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-14-(Dimethylamino)-4-oxo-2,3,15,16-tetraazabicyclo [10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-14-(4-Morpholinyl)-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5 -yl]methyl}-N-hydroxyformamide; and

N-{[(4R)-3,15-Dioxo-1,2-diazacyclopentadecan-4-yl]methyl}-N-hydroxyformamide; or

a pharmaceutically acceptable salt thereof.

5. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein Y represents —C(O)—.

6. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein Y represents a covalent bond.

7. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein R represents a covalent bond.

8. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein R represents heteroarylene.

9. The compound according to claim 8 , or a pharmaceutically acceptable salt thereof, wherein R represents 1,3,5-triazinyl; 1,3,5-triazinyl substituted with one dimethylamino, morpholinyl, or cyclopropylamino; 2-pyrimidinyl; or 2-pyrimidinyl substituted with one methyl, dimethylamino, or morpholinyl.

10. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein Z represents —CH 2 —; and m is equal to 0.

11. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein n is 5, 6, 7, or 9.

12. The compound according to claim 3 wherein

Y represents —C(O)— or a covalent bond:

R represents 1,3,5-triazinyl; 1,3,5-triazinyl substituted with one dimethylamino, morpholinyl, or cyclopropylamino; 2-pyrimidinyl; or 2-pyrimidinyl substituted with one methyl, dimethylamino, or morpholinyl; or a covalent bond;

Z represents —CH 2 —;

m is equal to 0; and

n is 5, 6, 7; or 9; or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier.